|Bid||0.8000 x 1300|
|Ask||0.0000 x 2200|
|Day's range||1.8701 - 2.2000|
|52-week range||1.8400 - 6.4600|
|Beta (5Y monthly)||-0.14|
|PE ratio (TTM)||N/A|
|Earnings date||09 Nov 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||8.00|
Armata Pharmaceuticals, Inc. (ARMP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Armata Pharmaceuticals, Inc. (ARMP) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the company will participate in the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage, which is being held virtually on November 30, 2022.